These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 3266646

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro activation of lymphocytes by interleukin 2 in patients with renal cell carcinoma.
    Ziegelbaum MM, Finke JH, Tubbs R, Montie JE, Pontes JE, Lewis I.
    Urology; 1989 Feb; 33(2):106-9. PubMed ID: 2783793
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990 Feb; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 8. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
    Belldegrun A, Uppenkamp I, Rosenberg SA.
    J Urol; 1988 Jan; 139(1):150-5. PubMed ID: 3257274
    [Abstract] [Full Text] [Related]

  • 9. In vivo distribution of recombinant interleukin-2-activated autologous lymphocytes administered by intra-arterial infusion in patients with renal cell carcinoma.
    Morita T, Yonese Y, Minato N.
    J Natl Cancer Inst; 1987 Mar; 78(3):441-50. PubMed ID: 3102826
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Anti-tumor effect of LAK (lymphokine activated killer) cells against human bladder tumors transplanted to nude mouse].
    Tsujihashi H, Ishihara H, Nakanishi A, Matsuda H, Uejima S, Akiyama T, Kurita T.
    Nihon Hinyokika Gakkai Zasshi; 1989 Feb; 80(2):204-9. PubMed ID: 2787443
    [Abstract] [Full Text] [Related]

  • 12. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T.
    J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Study on adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) for renal cell carcinoma--amplification of IL-2-elicited TIL proliferation by OKT3-monoclonal antibody].
    Hayakawa M, Sisido S, Higa I, Koyama Y, Hatano T, Osawa A.
    Nihon Hinyokika Gakkai Zasshi; 1990 Jan; 81(1):103-9. PubMed ID: 2304307
    [Abstract] [Full Text] [Related]

  • 16. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA.
    Cancer Res; 1988 Oct 15; 48(20):5864-7. PubMed ID: 3139285
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Adoptive immunotherapy of malignant diseases using normal allogeneic LAK cells].
    Kimoto Y, Tanji Y, Tanaka T, Taguchi T.
    Gan To Kagaku Ryoho; 1987 Jun 15; 14(6 Pt 1):1884-9. PubMed ID: 3496050
    [Abstract] [Full Text] [Related]

  • 19. [Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation].
    Nomura K, Fujioka T.
    Nihon Hinyokika Gakkai Zasshi; 1993 May 15; 84(5):831-40. PubMed ID: 8320888
    [Abstract] [Full Text] [Related]

  • 20. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M, Combaret V, Blay JY, Capdeville R, Zhou DC, Clapisson G, Chouaib S, Franks CR, Philip T.
    Eur Cytokine Netw; 1990 May 15; 1(4):221-7. PubMed ID: 2104243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.